Extraskeletal osteosarcoma harboring ETV6::NTRK3 fusion treated successfully with larotrectinib: a case study
This case represents the first reported instance of ESOS with an NTRK fusion. The rapid and sustained response to larotrectinib highlights the potential of precision medicine in managing rare and aggressive tumors, emphasizing the importance of molecular profiling to identify actionable targets.
Authors
- Kristijan Skok (ORCID: https://orcid.org/0000-0002-3027-8164)
- Bernadette Liegl‐Atzwanger (ORCID: https://orcid.org/0000-0003-2229-5535)
- Joanna Szkandera (ORCID: https://orcid.org/0000-0002-2217-893X)
- Sonja Hasenschwandtner
- Andreas Reichinger (ORCID: https://orcid.org/0000-0002-2835-5634)
- Andreas Leithner (ORCID: https://orcid.org/0000-0002-2598-2325)
- Christian Viertler (ORCID: https://orcid.org/0000-0003-3729-2900)
- Raphael Gassner
- Florian Ochsenhofer (ORCID: https://orcid.org/0009-0008-2401-960X)
Institutions
- Johannes Kepler University of Linz (AT)
- Medical University of Graz (AT)
- AGO Austria (AT)
Publication Details
- Journal
- Communications Medicine
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1038/s43856-025-01184-z
- Primary Topic
- Sarcoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Karl-Franzens-Universität Graz
- Medizinische Universität Graz